BrainsWay's Accelerated Deep TMS Protocol Receives Draft Coverage from Highmark Blue Cross Blue Shield
Summary
BrainsWay announced that Highmark Blue Cross Blue Shield has issued a draft medical policy to cover its accelerated Deep TMS protocol for adolescent and adult major depressive disorder, significantly expanding market access for the recently FDA-cleared treatment.
Key Events
-
Draft Coverage Policy Issued
Highmark Blue Cross Blue Shield released a draft medical policy to cover BrainsWay's accelerated Deep TMS™ protocol.
-
Expanded Patient Population
The draft policy extends coverage to both adolescent and adult patients with major depressive disorder (MDD).
-
Accelerated Protocol Coverage
The policy covers the SWIFT™ protocol, which offers a shorter, more flexible treatment course (38 sessions over 6 days acute + 4 weeks maintenance).
-
Significant Payer Impact
Highmark covers over seven million lives, representing a substantial market opportunity for BrainsWay.
Analysis
This development is highly positive for BrainsWay as it signals broader reimbursement for its recently FDA-cleared accelerated Deep TMS protocol. Highmark Blue Cross Blue Shield covers over seven million lives, making this a substantial market access expansion. The accelerated protocol, requiring fewer clinic visits, could drive increased adoption and revenue growth for the company. While currently a draft, the anticipated February 2026 effective date suggests strong progress towards formal adoption.
At the time of this filing, BWAY was trading at $22.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $439.6M. The 52-week trading range was $7.84 to $24.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.